An estimated one million Americans have Parkinson’s disease. Nobody knows how many of them also are infected with COVID-19, but the experts do offer sound advice about how Parkinson’s patients can avoid getting sick in the first place. Rachel Dolhun, MD, is vice-president of medical communications at the New York-based…
As the world frantically battles coronavirus, a leading Dutch neurologist warns of the next global pandemic — and this one, he says, is almost entirely of our own making. Bastiaan Bloem, MD, a neurologist and professor at Radboud University Nijmegen Medical Center, says that over the next 20 years,…
Within a few years, doctors will be able to remotely evaluate patients for their risk of developing Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia — without having to hook them up to expensive, cumbersome machines generally found only in hospitals. That’s the vision of Israeli entrepreneur Nathan…
For years, Israeli neurologist Tamar Flash has had a fascination with the octopus, and the way the invertebrate’s eight arms propel it effortlessly through the water. She’s convinced this has major implications for diagnosing and treating Parkinson’s disease — and possible other disorders as well. “My major interest is…
These days, people with Parkinson’s disease tend to ask their doctors more questions about cannabis than any other subject; yet, few physicians have adequate answers for them. So says a new survey announced by the Parkinson’s Foundation, which plans a conference on that subject next month in Denver. The…
Warning the reporter accompanying him not to take any pictures, veteran horticulturalist Michael Castleman punches an electronic code and unlocks the door to Room 209, nicknamed the “Mother Room.” Photography is indeed forbidden inside this living vault, which contains 20 phenotypes of cannabis plants thriving under the glare of 25…
Ohio’s Cleveland Clinic will officially become a Parkinson’s Foundation Center of Excellence on Oct. 2, followed by the Medical University of South Carolina in Charleston on Oct. 4, and the Cleveland Clinic Nevada in Las Vegas on Oct. 19. Next month’s three plaque unveiling ceremonies will bring the number of…
Nearly half a year after news reports surfaced about deaths allegedly linked to Nuplazid (pimavanserin) — a therapy for Parkinson’s patients with disease-related psychosis — the U.S. Food and Drug Administration says it could not find any new or unexpected safety concerns with the controversial treatment. The agency said in…
The U.S. Food and Drug Administration is keeping close watch on the use of Nuplazid (pimavanserin) by Parkinson’s patients with disease-related psychosis, but at present sees no reasons to change the existing warnings placed on the medication — sold by Acadia Pharmaceuticals — when first approved. The FDA stated…
Get regular updates to your inbox.